ライフサイエンスコーパス: urokinase

1 , where it is cleaved into active plasmin by urokinase.

2 tissue-type plasminogen activator (tPA), and urokinase.

3 protease-activated receptor-2 (PAR2) and pro-urokinase.

4 y to form covalent inhibitory complexes with urokinase.

5 ecovery was similar to high-dose nontargeted urokinase (500 U/g body weight).

6 nstrated in total hospital stay: VATS versus urokinase (8 [4-17] d and 7 [4-25] d) (p = 0.645); failu

7 We previously generated PA-U2-R200A, a urokinase-activated PA variant with LF-binding subsite I

8 anthrax toxin, PrAgU2/FP59, composed of the urokinase-activated protective antigen and a fusion prot

9 tivator inhibitor 1 (PAI-1), a member of the urokinase activator system that is involved in tumor met

10 plasma membrane cationic current, inhibiting urokinase activity and cell invasion.

11 the urokinase receptor, differences in renal urokinase activity did not account for the increased fib

12 n retinal angiogenesis and a 40% decrease in urokinase activity in the retina.

13 e in endothelial cells mediated by increased urokinase activity.

14 lasminogen in human serum in the presence of urokinase (an activator that converts plasminogen to pla

15 stration resulted in increased extracellular urokinase and collagen degradation.

16 had a minor effect on permeability, whereas urokinase and desmoteplase were ineffective.

17 HGF stimulated the secretion of urokinase and its receptor, uPAR, in isolated retinal en

18 mug/mg hydrogel while the mid-sized protein urokinase and large monoclonal antibody rituximab load a

19 nd mRNA expression as well as a reduction of urokinase and matrix metalloproteinase (MMP)-2/MMP-9 act

20 Urokinase and recombinant tissue plasminogen activator a

21 nolysis is considered marginal compared with urokinase and tissue plasminogen activator.

22 Despite its function as an inhibitor of urokinase and tissue-type plasminogen activator (PA), PA

23 nce in clinical outcome between intrapleural urokinase and VATS for the treatment of childhood empyem

24 chemokine (C-X-C motif) ligand 2, Nidogen1, urokinase, and matrix metalloproteinase 3.

25 ally, the thrombolytic zymogens plasminogen, urokinase, and plasma kallikrein have all been shown to

26 vitro with model proteins salmon calcitonin, urokinase, and rituximab to determine the effects of par

27 o tested release of profibrinolytic enzymes, urokinase, and tissue plasminogen activator (TPA) as a s

28 lated with agonists, and secretion of Hsp90, urokinase, and TPA was measured in the culture supernata

29 matrix metalloproteinase (MMP)-1 and -9, and urokinase- and tissue-type plasminogen activators.

30 prolonged with this high dose of nontargeted urokinase, but not with equally effective targeted scFvS

31 iant human single-chain low molecular weight urokinase construct that can be activated selectively by

32 After pretreatment with a urokinase-expressing adenovirus, these animals could be

33 with a central cone-shaped cavity where the urokinase fragment inserts.

34 eptokinase, tissue-plasminogen activator and urokinase have been developed to improve the therapeutic

35 and the role of the extracellular proteinase urokinase in facilitating this process was determined.

36 ereby uPAR ligation with its cognate ligand, urokinase, induces a motile phenotype in human lung fibr

37 Furthermore, after thrombolysis with urokinase, LIBS-MB ultrasound imaging allows monitoring

38 ble for the in vivo detection and imaging of urokinase-like plasminogen activator (uPA), which is a k

39 ted through its ability to directly regulate urokinase -mediated activation of plasminogen (Pg).

40 r percutaneous chest drain with intrapleural urokinase or primary VATS.

41 ibroblasts of urokinase plasmingen activator/urokinase plasmingen activator receptor (uPA/uPAR), an e

42 s have focused on the role in fibroblasts of urokinase plasmingen activator/urokinase plasmingen acti

43 lines, we identified elevated levels of the urokinase plasminogen activation receptor (uPAR, PLAUR)

44 We fused single-chain urokinase plasminogen activator (scuPA) to a small recom

45 -PA, we engineered and expressed a two-chain urokinase plasminogen activator (tcu-PA) cleavage-resist

46 plasminogen activator receptor (u-PAR) binds urokinase plasminogen activator (u-PA) and participates

47 )-9, tissue plasminogen activator (tPA), and urokinase plasminogen activator (uPA) activities were as

48 Urokinase plasminogen activator (uPA) and its receptor (

49 acellular matrix degrading proteases such as urokinase plasminogen activator (uPA) and matrix metallo

50 Urokinase plasminogen activator (uPA) and PA inhibitor t

51 We compared the PAR-dependent expression of urokinase plasminogen activator (uPA) and plasminogen ac

52 e tissue plasminogen activator (tPA) and the urokinase plasminogen activator (uPA) associate with the

53 f certain tumor-associated proteases such as urokinase plasminogen activator (uPA) can be a hallmark

54 Urokinase plasminogen activator (uPA) converts plasminog

55 istance to EGFR TKIs, elevated expression of urokinase plasminogen activator (uPA) drives signaling t

56 escue experiments demonstrate that exogenous urokinase plasminogen activator (uPA) expression can res

57 Two of these antibodies compete against urokinase plasminogen activator (uPA) for uPAR binding,

58 followed by delayed synthesis and release of urokinase plasminogen activator (uPA) from injured brain

59 nisms involved in differential regulation of urokinase plasminogen activator (uPA) gene expression ar

60 Increased expression of urokinase plasminogen activator (uPA) has been reported

61 Urokinase plasminogen activator (uPA) is a biomarker and

62 that platelet (PLT) alpha granule-delivered urokinase plasminogen activator (uPA) is highly effectiv

63 Urokinase plasminogen activator (uPA) is inhibited by PN

64 t tissue-type plasminogen activator (tPA) or urokinase plasminogen activator (uPA) might be important

65 Here, we show that siRNA targeted to the urokinase plasminogen activator (uPA) promoter induced e

66 In the course of retargeting gD to the urokinase plasminogen activator (uPA) receptor for poten

67 mediates lysophosphatidic acid (LPA)-induced urokinase plasminogen activator (uPA) upregulation in ov

68 The urokinase plasminogen activator (uPA) was the first iden

69 y shown to down-regulate tumor expression of urokinase plasminogen activator (uPA), a protease linked

70 of major players of cell migration, such as urokinase plasminogen activator (uPA), its inhibitor pla

71 CD38B treatment increased endocytosis of the urokinase plasminogen activator (uPA), its receptor (uPA

72 n of both chitosan, targeting acidic pH, and urokinase plasminogen activator (UPA), targeting UPAR.

73 use fibrotic Mfs secrete elevated amounts of urokinase plasminogen activator (uPA), we tested whether

74 f the primary biochemical target of SerpinB2-urokinase plasminogen activator (uPA).

75 been correlated with increased expression of urokinase plasminogen activator (uPA).

76 or FIXa inhibiton based on its homology with urokinase plasminogen activator (uPA).

77 s efficacy is due to the effects of t-PA and urokinase plasminogen activator (uPA).

78 The in vivo effects of APs were tested in urokinase plasminogen activator (uPA)/severe combined im

79 ell culture, and animal models implicate the urokinase plasminogen activator (uPA)/uPA receptor (uPAR

80 removal by healthy cardiocytes and increases urokinase plasminogen activator (uPA)/uPA receptor (uPAR

81 f this study was to evaluate the role of the urokinase plasminogen activator (uPA)/uPA receptor (uPAR

82 roponin I; matrix metalloproteinase (MMP)-2; urokinase plasminogen activator (uPA); urokinase plasmin

83 ly inhibited the active form of the protease urokinase plasminogen activator (uPA, PLAU).

84 odes SerpinB2, an inhibitor of extracellular urokinase plasminogen activator and deletion of DUSP5 ac

85 of angiogenin led to increased activation of urokinase plasminogen activator and generation of active

86 e NF-kappaB pathway, increased expression of urokinase plasminogen activator and matrix metalloprotei

87 Components of the fibrinolytic pathway (urokinase plasminogen activator and plasmin) are elabora

88 EndoPredict, PAM50, Breast Cancer Index, and urokinase plasminogen activator and plasminogen activato

89 r inhibitor-1 (PAI-1), a potent inhibitor of urokinase plasminogen activator and tissue plasminogen a

90 eam target genes matrix metalloproteinase 9, urokinase plasminogen activator and vascular endothelial

91 The urokinase plasminogen activator binds to its cellular re

92 sminogen and was completely abrogated by the urokinase plasminogen activator inhibitor-1 and serine p

93 or activation by matrix metalloproteases and urokinase plasminogen activator into two of these varian

94 the serine protease thrombin and release the urokinase plasminogen activator loaded into the polymer

95 The soluble cleaved urokinase plasminogen activator receptor (scuPAR) is a c

96 te the potential association between soluble urokinase plasminogen activator receptor (suPAR) and inc

97 Soluble urokinase plasminogen activator receptor (suPAR) indepen

98 Systemic soluble urokinase plasminogen activator receptor (suPAR) is a ci

99 We have previously observed that soluble urokinase plasminogen activator receptor (suPAR) prevent

100 We investigated whether soluble urokinase plasminogen activator receptor (suPAR), a mark

101 tein (CRP), procalcitonin (PCT), and soluble urokinase plasminogen activator receptor (suPAR).

102 Urokinase plasminogen activator receptor (u-PAR) binds u

103 Interactions between urokinase plasminogen activator receptor (uPAR) and its

104 Given recent evidence implicating the urokinase plasminogen activator receptor (uPAR) as a "do

105 Western blot analysis were used to quantify urokinase plasminogen activator receptor (uPAR) expressi

106 The urokinase plasminogen activator receptor (uPAR) has emer

107 Extensive evidence implicates the urokinase plasminogen activator receptor (uPAR) in tumor

108 Urokinase plasminogen activator receptor (uPAR) is known

109 Urokinase plasminogen activator receptor (uPAR), a cellu

110 ing strategy: 1) an elevated tumor receptor, urokinase plasminogen activator receptor (UPAR), and 2)

111 s identify the subcellular relocalization of urokinase plasminogen activator receptor (uPAR), LIM and

112 Transcripts of the urokinase plasminogen activator receptor (uPAR), which f

113 ) mutually block each other's binding to the urokinase plasminogen activator receptor (uPAR).

114 ace expression levels of alpha5 integrin and urokinase plasminogen activator receptor (uPAR).

115 P)-2; urokinase plasminogen activator (uPA); urokinase plasminogen activator receptor (uPAR); plasmin

116 morphisms in the asthma susceptibility gene, urokinase plasminogen activator receptor (uPAR/PLAUR) ha

117 Sirt6 also reduces urokinase plasminogen activator receptor expression, whi

118 in hemangioma-derived stem cells, including urokinase plasminogen activator receptor, interleukin-6,

119 llagen receptors mannose receptor (Mrc1) and urokinase plasminogen activator receptor-associated prot

120 icits in intracellular collagen degradation (urokinase plasminogen activator receptor-associated prot

121 -50% of endosomes containing proteins of the urokinase plasminogen activator system (uPAS) to relocat

122 l fragment of the receptor binding domain of urokinase plasminogen activator to the surface of functi

123 c proteins matrix metalloproteinase-9, nm23, urokinase plasminogen activator, and cyclooxygenase-2.

124 r, human epidermal growth factor receptor 2, urokinase plasminogen activator, plasminogen activator i

125 be induced by exposure to specific ligands (urokinase plasminogen activator, vitronectin), but not v

126 tor-mediated lysis being more efficient than urokinase plasminogen activator-mediated lysis.

127 d administered intravenously to HCV-infected urokinase plasminogen activator-severe combined immunode

128 g triggered by the non-MHC-I-related protein urokinase plasminogen activator.

129 nfluenzae or bound to PE, was accessible for urokinase plasminogen activator.

130 ates proprostasin and cell surface-bound pro-urokinase plasminogen activator.

131 ease matriptase and subsequent activation of urokinase plasminogen activator.

132 both vascular endothelial growth factor and urokinase plasminogen activator.

133 PAI-1 induces the internalization of urokinase plasminogen activator/receptor and integrin al

134 Humanized urokinase plasminogen activator/severe combined immunode

135 rts that it may be an alternative urokinase (urokinase plasminogen activator; uPA) receptor in additi

136 apoptotic cells) and pathologic roles of the urokinase-plasminogen activator/receptor system (leads t

137 Genetic reduction of the uPAR ligand urokinase prevented degradation of fibrin-rich thrombi a

138 olecule ligands in complex with the proteins urokinase, PTP-1B, and Chk-1.

139 Overexpression of soluble urokinase receptor (suPAR) causes pathology in animal mo

140 Recently, serum soluble urokinase receptor (suPAR) has been proposed as a cause

141 Here we report that serum soluble urokinase receptor (suPAR) is elevated in two-thirds of

142 Serum soluble urokinase receptor (suPAR) levels strongly predict incid

143 The urokinase receptor (u-PAR) which is largely regulated at

144 Hypoxia induces expression of the urokinase receptor (uPAR) and activates uPAR-dependent c

145 s significantly increased levels of cellular urokinase receptor (uPAR) and release increased amounts

146 e that in EGFRvIII-expressing GBM cells, the urokinase receptor (uPAR) functions as a major activator

147 The urokinase receptor (uPAR) is a cell-signaling receptor k

148 The urokinase receptor (uPAR) is a glycosylphosphatidylinosi

149 Neither the urokinase receptor (uPAR) nor the low-density lipoprotei

150 The urokinase receptor (uPAR) plays an important role in reg

151 The urokinase receptor (uPAR) promotes metastasis of human m

152 Here we show that induction of urokinase receptor (uPAR) signaling in podocytes leads t

153 here we report the sequestration behavior of urokinase receptor (uPAR), a glycosylphosphatidylinosito

154 The urokinase receptor (uPAR), expressed on the surface of m

155 ed growth factor, matrix metalloproteinases, urokinase receptor and varied small-molecule tyrosine ki

156 We found that uPAR ligation with the urokinase receptor binding domain (amino-terminal fragme

157 The three domains of urokinase receptor form a concave shape with a central c

158 provides insight into the flexibility of the urokinase receptor that enables its interaction with a w

159 The urokinase receptor urokinase-type plasminogen activator

160 Binding to the urokinase receptor was completely abolished while PAI-1

161 ocyte antigen, PLAUR (plasminogen activator, urokinase receptor) domain-containing (LYPD)-6B on alpha

162 Although Mrc2 associates with the urokinase receptor, differences in renal urokinase activ

163 hly colocalized on the cell surface with the urokinase receptor, uPAR.

164 Up-regulation of urokinase receptors is common during tumor progression a

165 tions on beta1 integrin function, endogenous urokinase receptors were first stably silenced in tumor

166 Urokinase reduction also ameliorated liver hemorrhage an

167 linked because the high affinity binding of urokinase regulates the binding of uPAR to matrix-embedd

168 as filtered plasminogen may be processed by urokinase, released from renal tubular epithelium, to ge

169 lasminogen activator" OR "streptokinase" OR "urokinase." Search was not limited by year of publicatio

170 m corneum from proteolysis via inhibition of urokinase, thereby maintaining the integrity and barrier

171 free mice treated with plasminogen activator urokinase to elevate MDSC have reduced levels of L-selec

172 ed extracellular activity of enzymes such as urokinase, triggering a proteolytic cascade, which culmi

173 ibrinolytic cascade by colocalizing with the urokinase type plasminogen activator and receptor comple

174 n through the expression of the receptor for urokinase type plasminogen activator.

175 is the main inhibitor of the tissue type and urokinase type plasminogen activators.

176 imary inhibitor of the tissue-type (tPA) and urokinase-type (uPA) plasminogen activators, has been im

177 A recombinant prodrug, single-chain urokinase-type plasminogen activator (scuPA) fused to an

178 tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) activities in

179 Here, we show that neurons release urokinase-type plasminogen activator (uPA) and astrocyte

180 The high affinity interaction between the urokinase-type plasminogen activator (uPA) and its glyco

181 assess whether preoperative plasma levels of urokinase-type plasminogen activator (uPA) and its solub

182 1) and diminishing the enzymatic activity of urokinase-type plasminogen activator (uPA) and matrix me

183 Urokinase-type plasminogen activator (uPA) and plasmin,

184 d the involvement of p53-mediated changes in urokinase-type plasminogen activator (uPA) and plasminog

185 models focus on the ability of uPAR to bind urokinase-type plasminogen activator (uPA) and promote p

186 tein, p53, and apoptosis with suppression of urokinase-type plasminogen activator (uPA) and the uPA r

187 sly demonstrated that the expression of both urokinase-type plasminogen activator (uPA) and the uPA r

188 rpin inhibitor of the plasminogen activators urokinase-type plasminogen activator (uPA) and tissue pl

189 ay regulate cardiac fibrosis by inactivating urokinase-type plasminogen activator (uPA) and ultimatel

190 In addition, urokinase-type plasminogen activator (uPA) and uPA recep

191 Mice lacking urokinase-type plasminogen activator (uPA) are highly su

192 s cells produced more of the serine protease urokinase-type plasminogen activator (uPA) as compared w

193 his study identifies the extracellular PAI-1/urokinase-type plasminogen activator (uPA) balance as an

194 t of peripheral tolerance) actually produced urokinase-type plasminogen activator (uPA) during tolera

195 Sustained urokinase-type plasminogen activator (uPA) expression is

196 Urokinase-type plasminogen activator (uPA) is a serine p

197 Urokinase-type plasminogen activator (uPA) is a serine p

198 Urokinase-type plasminogen activator (uPA) is expressed

199 Urokinase-type plasminogen activator (uPA) is expressed

200 hypothesized that Mp-specific expression of urokinase-type plasminogen activator (uPA) is sufficient

201 Urokinase-type plasminogen activator (uPA) participates

202 Plasminogen activation catalyzed by urokinase-type plasminogen activator (uPA) plays an impo

203 We hypothesized that urokinase-type plasminogen activator (uPA) promotes musc

204 ree-domain clamp of Argos also resembles the urokinase-type plasminogen activator (uPA) receptor, whi

205 Genetic absence of the urokinase-type plasminogen activator (uPA) reduces arthr

206 Urokinase-type plasminogen activator (uPA) regulates ang

207 ave a significant reduction in expression of urokinase-type plasminogen activator (uPA) relative to t

208 Plasminogen activation by urokinase-type plasminogen activator (uPA) was markedly

209 Interaction of urokinase-type plasminogen activator (uPA) with its rece

210 such as matrix metalloproteinase (MMP)-9 and urokinase-type plasminogen activator (uPA), in human pro

211 ficient cells, which secreted high levels of urokinase-type plasminogen activator (uPA), invaded exte

212 The trypsin-like serine protease, urokinase-type plasminogen activator (uPA), is central i

213 g factors, such as interleukin (IL)-8, IL-6, urokinase-type plasminogen activator (uPA), or uPA recep

214 Tobacco smoke induced the expression of urokinase-type plasminogen activator (uPA), resulting in

215 Plasminogen can be activated to plasmin by urokinase-type plasminogen activator (uPA), tissue-type

216 as applied to the screening of inhibitors of urokinase-type plasminogen activator (uPA), which is a p

217 ilencing expression of endogenously produced urokinase-type plasminogen activator (uPA), which is nec

218 face receptor capable of not only focalizing urokinase-type plasminogen activator (uPA)-mediated fibr

219 LAM lesions and angiomyolipomas overexpress urokinase-type plasminogen activator (uPA).

220 closed as potent and selective inhibitors of urokinase-type plasminogen activator (uPA).

221 peptide based on consensus cleavage motif of urokinase-type plasminogen activator (uPA).

222 iring the proteolytic cascade of cathepsin B/urokinase-type plasminogen activator (uPA)/matrix metall

223 In addition, we demonstrate that the urokinase-type plasminogen activator (uPA)/uPA receptor

224 Mice deficient in urokinase-type plasminogen activator (uPA-/-) exhibit de

225 ts displayed moderately reduced single-chain urokinase-type plasminogen activator activation.

226 t the effect of L-MIM involves a decrease in urokinase-type plasminogen activator activity.

227 greatly reduced the activity of both tPA and urokinase-type plasminogen activator after HI.

228 d secretion of matrix metalloproteinases and urokinase-type plasminogen activator and an increase in

229 at the translational level by eIF3e included urokinase-type plasminogen activator and apoptotic regul

230 ement with these findings, reduced levels of urokinase-type plasminogen activator and elevated levels

231 turn induced expression of VEGF, MMP-9, and urokinase-type plasminogen activator and increased migra

232 ation of collagen IV, and their secretion of urokinase-type plasminogen activator and its receptor.

233 serpin inhibits tPA and, to a lesser extent, urokinase-type plasminogen activator and plasmin.

234 mmune-deficient transgenic mice carrying the urokinase-type plasminogen activator gene driven by the

235 icellular proteolytic cascades by activating urokinase-type plasminogen activator on the cell surface

236 in absence of ADAMTS13, after activation by urokinase-type plasminogen activator or the thrombolytic

237 an effect on the expression/function of the urokinase-type plasminogen activator protease uPA/uPAR s

238 Circulating levels of soluble forms of urokinase-type plasminogen activator receptor (suPAR) ar

239 Recent studies describe soluble urokinase-type plasminogen activator receptor (suPAR) as

240 Relatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) ha

241 Serum soluble urokinase-type plasminogen activator receptor (suPAR) is

242 ulin (beta-2 m), neopterin and suPAR soluble urokinase-type plasminogen activator receptor (suPAR) wa

243 Increased plasma level of soluble urokinase-type plasminogen activator receptor (suPAR) wa

244 In addition, Pdcd4 knockdown stimulates urokinase-type plasminogen activator receptor (u-PAR) an

245 elial growth factor results in clustering of urokinase-type plasminogen activator receptor (uPAR) and

246 s accompanied by increased expression of the urokinase-type plasminogen activator receptor (uPAR) and

247 Signaling by urokinase-type plasminogen activator receptor (uPAR) can

248 a serine proteinase that upon binding to the urokinase-type plasminogen activator receptor (uPAR) cat

249 The urokinase-type plasminogen activator receptor (uPAR) dri

250 in the mid-1980s, the cell membrane-anchored urokinase-type plasminogen activator receptor (uPAR) has

251 The urokinase-type plasminogen activator receptor (uPAR) has

252 explore the potential of PET imaging of the urokinase-type plasminogen activator receptor (uPAR) in

253 The urokinase receptor urokinase-type plasminogen activator receptor (uPAR) is

254 The urokinase-type plasminogen activator receptor (uPAR) is

255 The urokinase-type plasminogen activator receptor (uPAR) is

256 cells, interaction between vitronectin with urokinase-type plasminogen activator receptor (uPAR) on

257 The urokinase-type plasminogen activator receptor (uPAR) pro

258 Expression levels of the urokinase-type plasminogen activator receptor (uPAR) rep

259 ule (ARM) that is capable of recognizing the urokinase-type plasminogen activator receptor (uPAR), a

260 surface or secreted factors, including CD73, urokinase-type plasminogen activator receptor (uPAR), an

261 se partitioning, co-immunoprecipitation with urokinase-type plasminogen activator receptor (uPAR), an

262 ling pathways downstream of the EGFR and the urokinase-type plasminogen activator receptor (uPAR); ho

263 dinated by many receptors, in particular the urokinase-type plasminogen activator receptor (uPAR, CD8

264 through the interaction with a region of the urokinase-type plasminogen activator receptor (uPAR88-92

265 phosphatidylinositol-linked proteins such as urokinase-type plasminogen activator receptor and endoth

266 n of epidermal growth factor receptor and/or urokinase-type plasminogen activator receptor in a varie

267 ive action of cell surface-associated HS and urokinase-type plasminogen activator receptor in the acc

268 ncoding the antimicrobial peptides antigen-6/urokinase-type plasminogen activator receptor related pr

269 the rise of nephropathy biomarkers, soluble urokinase-type plasminogen activator receptor, suPAR and

270 The overexpression of urokinase-type plasminogen activator receptors (uPARs) r

271 ty of C4BP, the activation of plasminogen by urokinase-type plasminogen activator to active plasmin w

272 Bound to BBA70, plasminogen activated by urokinase-type plasminogen activator was able to degrade

273 ould lead to drug-entrapped vascular grafts: urokinase-type plasminogen activator was entrapped withi

274 rix metalloproteinase-9 and the secretion of urokinase-type plasminogen activator while increasing ti

275 immunodeficient BALB-DeltaRAG/gamma(c) -uPA (urokinase-type plasminogen activator) mice, freshly thaw

276 comitant increased expression of its target, urokinase-type plasminogen activator, a known tumor-asso

277 variant failed to activate the single-chain urokinase-type plasminogen activator, and the G221A and

278 the inhibition of interleukin (IL)-6, IL-8, urokinase-type plasminogen activator, and VEGF productio

279 n (FN)-1, plasminogen activator inhibitor-1, urokinase-type plasminogen activator, caveolin-1 and Slu

280 upon activation of PepO-bound plasminogen by urokinase-type plasminogen activator, generated plasmin

281 in vivo efficacy of mAb16-71 in "human liver urokinase-type plasminogen activator, severe combined im

282 by a compensatory increase in expression of urokinase-type plasminogen activator, which activates uP

283 (6) integrin, called alpha(6)p, generated by urokinase-type plasminogen activator-dependent cleavage

284 al (Beas2B) cells decreased basal as well as urokinase-type plasminogen activator-induced PAI-1 expre

285 activities of matrix metalloproteinase-2 and urokinase-type plasminogen activator.

286 oteins intercellular adhesion molecule-1 and urokinase-type plasminogen activator.

287 iation, and this cleavage may be mediated by urokinase-type plasminogen activator.

288 th factor 1, leukemia inhibitory factor, and urokinase-type plasminogen activator.

289 U1) by costimulation with phorbol esters and urokinase-type plasminogen activator.

290 SkzL enhances the activation of [Glu]Pg by urokinase (uPA) approximately 20-fold, to a maximum rate

291 ), able to interact with FPRs and to mediate urokinase (uPA) or fMLF-dependent cell migration.

292 otein in p53(-/-) cells suppressed basal and urokinase (uPA)-induced cell surface uPAR protein and in

293 A and oligonucleotides bind tissue-(tPA) and urokinase (uPA)-type plasminogen activators, plasmin, an

294 Urokinase (uPA, urinary plasminogen activator) is a seri

295 hich could be inhibited by the disruption of urokinase/uPAR interactions with the A6 peptide.

296 given reports that it may be an alternative urokinase (urokinase plasminogen activator; uPA) recepto

297 ety of ligands and a basis for the design of urokinase-urokinase receptor antagonists.

298 augmented by any of the agonists tested but urokinase was released by IL-1, TNF-alpha, and thrombin

299 IL-1 and TNF-alpha stimulate release of urokinase, which can convert plasminogen to plasmin and

300 o 30 patients, and 7 patients received local urokinase without thrombectomy.